1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder
Elanco Europe Ltd., Form 2, Bartley Way, Bartley Wood Business Park, Hook RG27 9XA, United Kingdom

Manufacturer responsible for batch release
KVP Pharma + Veterinär Produkte GmbH, Projensdorfer Str. 324, 24106 Kiel, Germany

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Advantix® Spot-on solution for dogs up to 4 kg
Advantix® Spot-on solution for dogs over 4 kg up to 10 kg
Advantix® Spot-on solution for dogs over 10 kg up to 25 kg
Advantix® Spot-on solution for dogs over 25 kg up to 40 kg
Advantix® Spot-on solution for dogs over 40 kg up to 60 kg
imidacloprid, permethrin

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each pipette contains:

<table>
<thead>
<tr>
<th>Pipette</th>
<th>Imidacloprid</th>
<th>Permethrin</th>
<th>Butylhydroxytoluene (E321)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advantix® Spot-on solution for dogs ≤ 4 kg</td>
<td>40 mg</td>
<td>200 mg</td>
<td>0.4 mg</td>
</tr>
<tr>
<td>Advantix® Spot-on solution for dogs &gt; 4 ≤ 10 kg</td>
<td>100 mg</td>
<td>500 mg</td>
<td>1.0 mg</td>
</tr>
<tr>
<td>Advantix® Spot-on solution for dogs &gt; 10 ≤ 25 kg</td>
<td>250 mg</td>
<td>1250 mg</td>
<td>2.5 mg</td>
</tr>
<tr>
<td>Advantix® Spot-on solution for dogs &gt; 25 ≤ 40 kg</td>
<td>400 mg</td>
<td>2000 mg</td>
<td>4.0 mg</td>
</tr>
<tr>
<td>Advantix® Spot-on solution for dogs &gt;40kg ≤ 60kg</td>
<td>600 mg</td>
<td>3000 mg</td>
<td>6.0 ml</td>
</tr>
</tbody>
</table>

For dogs > 60 kg the appropriate combination with other sized pipettes should be used.

A clear yellowish to brownish spot-on solution.

4. INDICATIONS

For the treatment and prevention of flea (C. canis, C. felis) infestation and for the treatment of biting lice (Trichodectes canis) on dogs.

Fleas on dogs are killed within one day following treatment. One treatment prevents further flea infestation for four weeks. The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

The product has persistent acaricidal and repellent efficacy against tick infestations (Rhipicephalus sanguineus and Ixodes ricinus for four weeks, and Dermacentor reticulatus for three weeks).

By repelling and killing the tick vector Rhipicephalus sanguineus, the product reduces the likelihood of transmission of the pathogen Ehrlichia canis, thereby reducing the risk of canine ehrlichiosis. The reduction in risk has been shown in studies to commence from 3 days following application of the product and to persist for 4 weeks.

Ticks already on the dog may not be killed within two days after treatment and may remain attached and visible. Therefore the removal of ticks already on the dog at the time of treatment is recommended, in order to prevent them from attaching and having a blood meal.

One treatment provides repellent (anti-feeding) activity against sand flies (P. papatasi for two weeks and Phlebotomus perniciosus for three weeks), against mosquitoes (A. aegypti for two weeks and C. pipiens for four weeks) and against stable flies (S. calcitrans) for four weeks.

Reduction of the risk of infection with Leishmania infantum via transmission by sandflies (Phlebotomus perniciosus) for up to 3 weeks. The effect is indirect due to product's activity against the vector.

<table>
<thead>
<tr>
<th>Sand flies</th>
<th>P. perniciosus</th>
<th>3 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>P. papatasi</td>
<td>2 weeks</td>
<td></td>
</tr>
<tr>
<td>Mosquitoes</td>
<td>A. aegypti</td>
<td>2 weeks</td>
</tr>
<tr>
<td>C. pipiens</td>
<td>4 weeks</td>
<td></td>
</tr>
<tr>
<td>Stable flies</td>
<td>S. calcitrans</td>
<td>4 weeks</td>
</tr>
</tbody>
</table>

5. CONTRAINDICATIONS

In the absence of available data the product should not be used on puppies of less than 7 weeks of age or 1.5 kg of weight. According to the dog's body weight the corresponding Advantix® product must be used, see dosing scheme.

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

Do not use on cats.
6. ADVERSE REACTIONS

Application site itching and hair change (e.g. greasy fur) and vomiting were uncommonly observed in clinical studies. Other reactions like redness, inflammation and hair loss at the application site and diarrhea were reported rarely.

On very rare occasions, reactions in dogs including transient skin sensitivity (scratching and rubbing) or lethargy were reported in spontaneous (pharmacovigilance) reports. These reactions are generally self-resolving.

In very rare cases dogs may show behaviour changes (agitation, restlessness, whining or rolling), gastro-intestinal symptoms (hypersalivation, diminished appetite) and neurological signs such as unsteady movement and twitching in dogs susceptible to the ingredient permethrin. These signs are generally transient and self-resolving.

Poisoning following inadvertent oral uptake in dogs is unlikely but may occur in very rare cases. In this event, neurological signs such as tremor and lethargy can occur. Treatment should be symptomatic. There is no known specific antidote.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Dogs

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

The recommended minimum dose is:
10 mg/kg body weight (bw) imidacloprid and 50 mg/kg body weight (bw) permethrin.

For dogs > 60 kg the appropriate combination with other sized pipettes should be used.

To reduce re-infestation from emergence of new fleas, it is recommended to treat all dogs in a household. Other animals living in the same household should also be treated with a suitable product. To aid further in reducing environmental challenge, the additional use of a suitable environmental treatment against adult fleas and their developmental stages is recommended.

The product remains effective if the animal becomes wet. However, prolonged, intense exposure to water should be avoided. In cases of frequent water exposure the persistent efficacy may be reduced. In these cases do not retreat more frequently than once weekly.

If a dog requires a shampoo, it should be administered before applying Advantix® or at least 2 weeks after application, to optimise efficacy of the product.

In case of biting louse infestation, a further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

To protect a dog over the whole sand fly season, treatment should be compliantly continued throughout.

### Dosing Scheme

<table>
<thead>
<tr>
<th>Dogs (kg bw)</th>
<th>Trade name</th>
<th>Volume (ml)</th>
<th>Imidacloprid (mg/kg bw)</th>
<th>Permethrin (mg/kg bw)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 kg and less</td>
<td>Advantix® Spot-on for dogs up to 4 kg</td>
<td>0.4 ml</td>
<td>minimum of 10</td>
<td>minimum of 50</td>
</tr>
<tr>
<td>More than 4 to 10 kg</td>
<td>Advantix® Spot-on for dogs over 4 kg up to 10 kg</td>
<td>1.0 ml</td>
<td>10 - 25</td>
<td>50 - 125</td>
</tr>
<tr>
<td>More than 10 to 25 kg</td>
<td>Advantix® Spot-on for dogs over 10 kg up to 25 kg</td>
<td>2.5 ml</td>
<td>10 - 25</td>
<td>50 - 125</td>
</tr>
<tr>
<td>More than 25 to 40 kg</td>
<td>Advantix® Spot-on for dogs over 25 kg up to 40 kg</td>
<td>4.0 ml</td>
<td>10 - 16</td>
<td>50 - 80</td>
</tr>
<tr>
<td>More than 40 to 60 kg</td>
<td>Advantix® Spot-on for dogs over 40 kg up to 60 kg</td>
<td>6.0 ml</td>
<td>10 - 15</td>
<td>50 - 75</td>
</tr>
</tbody>
</table>

Method of Administration

Remove one pipette from the package. Hold applicator pipette in an upright position, twist and pull cap off. Turn the cap around and place the other end of cap back on pipette. Twist cap to break seal, then remove cap from pipette.
For dogs up to 10 kg body weight:
With the dog standing still, part the coat between the shoulder blades until the skin is visible. Place the tip of the pipette on the skin and squeeze firmly several times to empty the contents directly onto the skin (see figure 1).

For dogs over 10 kg body weight:
With the dog standing still, the entire contents of the Advantix® pipette should be applied evenly to four spots on the top of the back from the shoulder to the base of the tail. At each spot, part the hair until the skin is visible. Place the tip of the pipette on the skin and gently squeeze to expel a portion of the solution on the skin (see figure 2).

9. ADVICE ON CORRECT ADMINISTRATION

For external use only.
Apply only to undamaged skin.
Do not apply an excessive amount of solution at any one spot that could cause some of the solution to run off the side of the dog.

10. WITHDRAWAL PERIOD(S)

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
Do not freeze.
After opening the foil pouch store in a dry place at a temperature not above 30°C.
For 0.4 ml – 4.0 ml: Use within 24 months after opening the foil pouch or before EXP, whichever is shorter.
For 6.0 ml: Use within 12 months after opening the foil pouch or before EXP, whichever is shorter.

Do not use this veterinary medicinal product after the expiry date which is stated on the pipette, foil pouch, or carton after EXP. The expiry date refers to the last day of that month.

12. SPECIAL WARNINGS

Special warnings for each target species:

There may be an attachment of single ticks or bites by single sand flies or mosquitoes. For this reason, a transmission of infectious diseases by these parasites cannot be completely excluded if conditions are unfavourable. However, the product provides repellent (anti-feeding) activity against ticks, sand flies and mosquitoes, thus preventing the repelled parasites from taking a blood meal and thus reducing the risk of Canine Vector-Borne Disease (CVBD) transmission (diseases such as borreliosis, rickettsiosis, ehrlichiosis, leishmaniosis).

Immediate protection against sandfly bites is not documented. Treated dogs for the reduction of the risk of infection with *Leishmania infantum* via transmission by sandflies *P. perniciosus* should be kept in a protected environment during the first 24 hours after the initial treatment application.

It is recommended to apply the treatment at least 3 days before expected exposure to *E. canis*. With regard to *E. canis*, studies have demonstrated a reduced risk of canine ehrlichiosis in dogs exposed to *Rhipicephalus sanguineus* ticks infected with *E. canis* from 3 days following application of the product and to persist for 4 weeks.

Special precautions for use in animals

Care should be taken to avoid the content of the pipette coming into contact with the eyes or mouth of the recipient dogs.

Care should be taken to administer the product correctly as described under Method of Administration. In particular oral uptake due to the licking of the application site by treated or in-contact animals should be avoided.

Do not use on cats.

This product is extremely poisonous to cats and could be fatal due to the unique physiology of cats which is unable to metabolise certain compounds including permethrin. To prevent cats from being accidentally exposed to the product, keep treated dogs away from cats after treatment until the application site is dry. It is important to ensure that cats do not groom the site of application on a dog, which has been treated with this product. Seek veterinary advice immediately if this occurs.

Consult your veterinary surgeon before using the product on sick and debilitated dogs.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Avoid contact between the product and skin, eyes or mouth.
Do not eat, drink or smoke during application.
Wash hands thoroughly after use.
In case of accidental spillage onto skin, wash off immediately with soap and water.
People with known skin sensitivity may be particularly sensitive to this product.
The predominant clinical symptoms that in extremely rare case may be shown are transient sensory irritations of the skin like tingling, burning sensation or numbness.
If the product gets accidentally into the eyes, they should be thoroughly flushed with water.
If skin or if eye irritation persists obtain medical attention immediately and show the package insert to the physician.
Do not ingest. In case of accidental ingestion seek medical advice immediately and show the package leaflet or the label to the physician.
Treated dogs should not be handled especially by children until the application site is dry.
This may be ensured by treating the dogs e.g. in the evening. Recently treated dogs should not be allowed to sleep together with their owner, especially children.
In order to prevent children from getting access to pipettes, keep the pipette in the original packaging until ready for use and dispose of used pipettes immediately.

Other precautions:

As the product is dangerous to aquatic organisms, treated dogs must not under any circumstances be allowed into any type of surface water for at least 48 hours after treatment.
The solvent in Advantix® Spot-on solution may stain certain materials including leather, fabrics, plastics and finished surfaces. Allow the application site to dry before permitting contact with such materials.

Pregnancy and lactation:
The product can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:
None known.

Overdose (symptoms, emergency procedures, antidotes):
No adverse clinical signs were noted in healthy puppies or adult dogs exposed to 5x overdosage or for puppies whose mothers were treated with 3x overdosage of the product.

Incompatibilities:
None known.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

After use, replace cap on tube.
Medicines should not be disposed of via wastewater. Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
September 2020

15. OTHER INFORMATION

Advantix® Spot-on is an ectoparasiticide for topical use containing imidacloprid and permethrin. This combination acts as an insecticide, acaricide and as a repellent.

Imidacloprid is effective against adult fleas and larval flea stages. In addition to the adulticide flea efficacy of imidacloprid, a larvicidal flea efficacy in the surroundings of the treated pet has been demonstrated. Larval stages in the dog’s immediate surroundings are killed following contact with a treated animal.

Permethrin containing products are toxic to honey bees.

Pack sizes: 0.4 ml, 1.0 ml, 2.5 ml, 4.0 ml and 6.0 ml per pipette; packs containing 1, 2, 3, 4, 6 and 24 single-use pipette packs.
Not all pack sizes may be marketed.